It wouldn't be surprising to see some C-met deals coming. I recently started nibbling on both SGXP and ARQL, and figure that even without an imminent deal, they're likely good long term holdings.
>>> ARQL-OP-bet you see a decent trade in the stock in the next few weeks. Howard Liang expects SGXP (not rated) to announce a partnership on their preclinical C-met inhibitor this summer. Hearing there are 10 term sheets out for SGXP drug and shaping up to possibly be the richest preclinical biotech deal ever. ARQL's ARQ-197(c-MET inhib entering ph 2-pancreatic cancer mid:07) is currently partnered only in Jap. Expect the SGXP deal to significantly raise awareness of c-MET class and could be 9 bidders walking away from bidding looking to license a c-MET. T =$12. <<<
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM